ERP Clinical Trials

302 recruitingLast updated: May 29, 2026

There are 302 actively recruiting erp clinical trials across 58 countries. Studies span Not Applicable, Phase 2, Phase 3, Phase 1, Phase 4. Top locations include Beijing, Beijing Municipality, China, Beijing, China, Paris, France. Updated daily from ClinicalTrials.gov.


ERP Trials at a Glance

302 actively recruiting trials for erp are listed on ClinicalTrialsFinder across 6 cities in 58 countries. The largest study group is Not Applicable with 122 trials, with the heaviest enrollment activity in Beijing, Beijing, and Paris. Lead sponsors running erp studies include Beijing Tiantan Hospital, National Cancer Institute (NCI), and Taisho Pharmaceutical Co., Ltd..

Browse erp trials by phase

Treatments under study

About ERP Clinical Trials

Looking for clinical trials for ERP? There are currently 1 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new ERP trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about ERP clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 302 trials

Recruiting
Phase 3

Mirena for the Treatment of Nonatypical Endometrial Hyperplasia for 6 Months

Endometrial Hyperplasia
Bayer207 enrolled87 locationsNCT06904274
Recruiting
Phase 1Phase 2

Safety and Immunogenicity of Recombinant Varicella Zoster Virus Vaccine in People With HIV Who Have a CD4 Count Less Than 300 or Greater Than or Equal to 300 and a Healthy Control Population

Herpes Zoster
National Institute of Allergy and Infectious Diseases (NIAID)225 enrolled1 locationNCT05580458
Recruiting

Calcium Isotope Ratios to Assess Calcium Bone Balance in Dialysis Children Receiving Cinacalcet

Children Over 3 Undergoing Dialysis With Secondary Hyperparathyroidism
Hospices Civils de Lyon20 enrolled7 locationsNCT07007338
Recruiting
Not Applicable

Addressing the Double Burden of Malnutrition in Guatemala

Child malnutritionMaternal Obesity Complicating Pregnancy, Birth,or Puerperium
Brigham and Women's Hospital1,532 enrolled1 locationNCT06750120
Recruiting

Viral Infections in Healthy and Immunocompromised Hosts

Herpes LabialisCOVID-19Anogenital Herpes
National Institute of Allergy and Infectious Diseases (NIAID)1,000 enrolled1 locationNCT01306084
Recruiting

Molecular and Immunohistochemical Profiling of Tumors in Patients With Parathyroid Tumors

Primary HyperparathyroidismParathyroid Gland CarcinomaParathyroid Gland Atypical Adenoma+1 more
M.D. Anderson Cancer Center310 enrolled1 locationNCT03039439
Recruiting
Phase 2

Low Dose Tamoxifen With or Without Omega-3 Fatty Acids for Breast Cancer Risk Reduction

Breast CarcinomaBreast Ductal Carcinoma in SituBreast Atypical Hyperplasia+1 more
National Cancer Institute (NCI)66 enrolled3 locationsNCT06195306
Recruiting
Phase 3

A Study to Evaluate Atumelnant in Adults With Congenital Adrenal Hyperplasia

Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia
Crinetics Pharmaceuticals Inc.150 enrolled36 locationsNCT07144163
Recruiting
Not Applicable

Impact of Bright Light Therapy on Prader-Willi Syndrome

Body WeightPrader-Willi SyndromeBehavior+3 more
Maimonides Medical Center50 enrolled1 locationNCT05939453
Recruiting
Not Applicable

Planning Together: A Couple-based, Multi-level Prenatal Contraceptive Education Program for Economically Marginalized Families

Short Interpregnancy IntervalsMaternal Health Disparities
University of Tennessee Graduate School of Medicine60 enrolled1 locationNCT07214012
Recruiting
Phase 3

A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis

Hyperphosphatemia Patients on Hemodialysis
Taisho Pharmaceutical Co., Ltd.30 enrolled1 locationNCT07548840
Recruiting
Phase 2

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer

Breast CarcinomaBreast Ductal Carcinoma in SituBreast Atypical Hyperplasia+1 more
National Cancer Institute (NCI)80 enrolled4 locationsNCT05941520
Recruiting
Phase 2

Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial

Breast CarcinomaEstrogen Receptor-Positive Breast CarcinomaBreast Ductal Carcinoma in Situ+3 more
National Cancer Institute (NCI)200 enrolled11 locationsNCT06184750
Recruiting
Phase 3

A Clinical Study of TS-172 in Hyperphosphatemia Patients on Peritoneal Dialysis

Hyperphosphatemia Patients on Peritoneal Dialysis
Taisho Pharmaceutical Co., Ltd.30 enrolled1 locationNCT07548853
Recruiting
Not Applicable

Sacral Neuromodulation for Male Overactive Bladder (MOAB)

Prostate CancerProstatectomyBenign Prostatic Hyperplasia+3 more
Axonics, Inc.150 enrolled20 locationsNCT06511141
Recruiting
Phase 2Phase 3

Accuracy of 18F-Fluorocholine PET/MR and NeuroEXPLORER PET/CT Imaging for Localization of Parathyroid Tumors

Primary HyperparathyroidismParathyroid CancerMultiple Endocrine Neoplasias+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)193 enrolled1 locationNCT07444723
Recruiting
Phase 2

Y-4 to Treat the Postherpetic Neuralgia

Postherpetic NeuralgiaPregabalinY-4
Neurodawn Pharmaceutical Co., Ltd.160 enrolled1 locationNCT07275762
Recruiting

Natural History Study of Parathyroid Disorders

Multiple Endocrine Neoplasia Type 1Primary HyperparathyroidismParathyroid Cancer+2 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)3,000 enrolled1 locationNCT04969926
Recruiting
Phase 4

A Study to Evaluate the Effect of Recombinant Zoster Vaccine on New Diagnosis of Dementia in an Older Adult Population Aged 76 Years or Older in Finland

Herpes Zoster
GlaxoSmithKline33,609 enrolled8 locationsNCT07502560
Recruiting
Phase 2

Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)

KSHV Inflammatory Cytokine Syndrome (KICS)Kaposi Sarcoma Herpesvirus -Associated Multicentric Castleman Disease
National Cancer Institute (NCI)75 enrolled1 locationNCT06052618